Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

Recruiting N/A Interventional Study
Reccurent/Metastatic Solid Tumor Disease Prostate Cancer (Post Prostatectomy) Prostate Cancer Prostatic Neoplasms Neoplasm Recurrence, Local Biochemical Recurrence of Malignant Neoplasm of Prostate
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Male
Study type
Interventional
Purpose
Treatment
Participants needed
434 (estimated)
Sponsor
CHU de Quebec-Universite Laval · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Study Overview This research compares two types of post-operative salvage radiotherapy (SRT) for men with prostate cancer who have had surgery but show signs of recurrence (detectable PSA). The goal is to see if a shorter treatment schedule is as safe and effective as the standard schedule. Why is this study important? After prostate surgery, cancer can return in up to 70-80% of high-risk patient…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Histologically confirmed prostate adenocarcinoma. * Prior radical prostatectomy with detectable PSA (≥0.2 ng/mL). * No evidence of distant metastasis (confirmed via bone scan and CT/MRI or TEP-PSMA if PSA is above 0.5 ng /ml). * Patient with Nodal recurrence within the pelvis …
Contacts

Eric Vigneault, MD, MSc

418 691-5264

eric.vigneault.med@ssss.gouv.qc.ca

CONTACT

Damien Carignan, PhD

418 525-4444

damien.carignan@crchudequebec.ulaval.ca

CONTACT